Cargando…
1191. The Implementation of Nasal MRSA PCR for Pneumonia and Association with Antibiotic Use and Clinical Outcomes
BACKGROUND: Nasal MRSA PCR testing has been successfully implemented at many centers and limits vancomycin exposure among hospitalized patients with pneumonia. There are few studies of a Best Practice Alert (BPA) to direct nasal MRSA PCR use and vancomycin de-escalation in the absence of other stewa...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Oxford University Press
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10678713/ http://dx.doi.org/10.1093/ofid/ofad500.1031 |
_version_ | 1785150428357328896 |
---|---|
author | Fenlon, Luke A Fong, Karen Spivak, Emily S Imlay, Hannah |
author_facet | Fenlon, Luke A Fong, Karen Spivak, Emily S Imlay, Hannah |
author_sort | Fenlon, Luke A |
collection | PubMed |
description | BACKGROUND: Nasal MRSA PCR testing has been successfully implemented at many centers and limits vancomycin exposure among hospitalized patients with pneumonia. There are few studies of a Best Practice Alert (BPA) to direct nasal MRSA PCR use and vancomycin de-escalation in the absence of other stewardship oversight. On 1/2/2020, nasal MRSA PCR and a BPA were implemented at our institution. Providers ordering vancomycin for patients with an indication of pneumonia or undifferentiated sepsis were directed to order a nasal MRSA PCR and recommended to stop vancomycin if negative (Figure 1). Our aim was to examine the impact of BPAs implementation on vancomycin duration among patients with suspected pneumonia. [Figure: see text] METHODS: A retrospective chart review was conducted among hospitalized patients without prior MRSA PCR performed during their admission who had a listed indication of pneumonia or sepsis at the time of vancomycin order. Patients were categorized into “pre” (9/17/2018 – 1/1/2020) and “post” (1/2/2020 – 3/20/2021) cohorts based on date of vancomycin order. Demographics, comorbidities, and antibiotic duration were electronically extracted. Uni- and multivariable logistic models were used to examine the proportion of patients in the pre and post cohorts whose vancomycin was stopped within 24 hours of initial order. RESULTS: A total of 2,195 patients were included, 1210 in the pre-intervention and 985 in the post-intervention cohort. After BPA implementation, 771/985 (78%) patients received a nasal MRSA PCR. Vancomycin was discontinued within 24 hours after initiation in 384/1210 (32%) patients pre-intervention and 559/985 (57%) patients post-intervention (adjusted OR 2.92 [95% CI 2.44 – 3.49], p < 0.001) (Table 1). Although “high risk” patient factors (e.g. need for mechanical ventilation) were associated with longer durations, vancomycin duration was significantly shorter in the post-implementation cohort for all “high risk” sub-groups (Figure 2). [Figure: see text] [Figure: see text] CONCLUSION: BPA directed nasal MRSA PCR testing and vancomycin de-escalation effectively shortened duration of therapy among patients with suspected pneumonia. Utilizing a BPA directed approach can improve decision efficiency and allow valuable stewardship team resources to be allocated elsewhere. DISCLOSURES: All Authors: No reported disclosures |
format | Online Article Text |
id | pubmed-10678713 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Oxford University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-106787132023-11-27 1191. The Implementation of Nasal MRSA PCR for Pneumonia and Association with Antibiotic Use and Clinical Outcomes Fenlon, Luke A Fong, Karen Spivak, Emily S Imlay, Hannah Open Forum Infect Dis Abstract BACKGROUND: Nasal MRSA PCR testing has been successfully implemented at many centers and limits vancomycin exposure among hospitalized patients with pneumonia. There are few studies of a Best Practice Alert (BPA) to direct nasal MRSA PCR use and vancomycin de-escalation in the absence of other stewardship oversight. On 1/2/2020, nasal MRSA PCR and a BPA were implemented at our institution. Providers ordering vancomycin for patients with an indication of pneumonia or undifferentiated sepsis were directed to order a nasal MRSA PCR and recommended to stop vancomycin if negative (Figure 1). Our aim was to examine the impact of BPAs implementation on vancomycin duration among patients with suspected pneumonia. [Figure: see text] METHODS: A retrospective chart review was conducted among hospitalized patients without prior MRSA PCR performed during their admission who had a listed indication of pneumonia or sepsis at the time of vancomycin order. Patients were categorized into “pre” (9/17/2018 – 1/1/2020) and “post” (1/2/2020 – 3/20/2021) cohorts based on date of vancomycin order. Demographics, comorbidities, and antibiotic duration were electronically extracted. Uni- and multivariable logistic models were used to examine the proportion of patients in the pre and post cohorts whose vancomycin was stopped within 24 hours of initial order. RESULTS: A total of 2,195 patients were included, 1210 in the pre-intervention and 985 in the post-intervention cohort. After BPA implementation, 771/985 (78%) patients received a nasal MRSA PCR. Vancomycin was discontinued within 24 hours after initiation in 384/1210 (32%) patients pre-intervention and 559/985 (57%) patients post-intervention (adjusted OR 2.92 [95% CI 2.44 – 3.49], p < 0.001) (Table 1). Although “high risk” patient factors (e.g. need for mechanical ventilation) were associated with longer durations, vancomycin duration was significantly shorter in the post-implementation cohort for all “high risk” sub-groups (Figure 2). [Figure: see text] [Figure: see text] CONCLUSION: BPA directed nasal MRSA PCR testing and vancomycin de-escalation effectively shortened duration of therapy among patients with suspected pneumonia. Utilizing a BPA directed approach can improve decision efficiency and allow valuable stewardship team resources to be allocated elsewhere. DISCLOSURES: All Authors: No reported disclosures Oxford University Press 2023-11-27 /pmc/articles/PMC10678713/ http://dx.doi.org/10.1093/ofid/ofad500.1031 Text en © The Author(s) 2023. Published by Oxford University Press on behalf of Infectious Diseases Society of America. https://creativecommons.org/licenses/by/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Abstract Fenlon, Luke A Fong, Karen Spivak, Emily S Imlay, Hannah 1191. The Implementation of Nasal MRSA PCR for Pneumonia and Association with Antibiotic Use and Clinical Outcomes |
title | 1191. The Implementation of Nasal MRSA PCR for Pneumonia and Association with Antibiotic Use and Clinical Outcomes |
title_full | 1191. The Implementation of Nasal MRSA PCR for Pneumonia and Association with Antibiotic Use and Clinical Outcomes |
title_fullStr | 1191. The Implementation of Nasal MRSA PCR for Pneumonia and Association with Antibiotic Use and Clinical Outcomes |
title_full_unstemmed | 1191. The Implementation of Nasal MRSA PCR for Pneumonia and Association with Antibiotic Use and Clinical Outcomes |
title_short | 1191. The Implementation of Nasal MRSA PCR for Pneumonia and Association with Antibiotic Use and Clinical Outcomes |
title_sort | 1191. the implementation of nasal mrsa pcr for pneumonia and association with antibiotic use and clinical outcomes |
topic | Abstract |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10678713/ http://dx.doi.org/10.1093/ofid/ofad500.1031 |
work_keys_str_mv | AT fenlonlukea 1191theimplementationofnasalmrsapcrforpneumoniaandassociationwithantibioticuseandclinicaloutcomes AT fongkaren 1191theimplementationofnasalmrsapcrforpneumoniaandassociationwithantibioticuseandclinicaloutcomes AT spivakemilys 1191theimplementationofnasalmrsapcrforpneumoniaandassociationwithantibioticuseandclinicaloutcomes AT imlayhannah 1191theimplementationofnasalmrsapcrforpneumoniaandassociationwithantibioticuseandclinicaloutcomes |